Fortrea Revenue Falls 1.4 Percent in Third Quarter

The contract research provider's quarterly revenue contraction signals shifting demand for clinical trial services.

Updated on Oct. 29, 2026 in Corporate Finance

Bold flat-color editorial illustration featuring a geometric representation of clinical research architecture, evoking institutional financial performance analysis. — Fortrea Holdings Inc. reported a 1.4% revenue decline to $691.5 million in the third quarter of 2026 amid shifting clinical trial demand. AI Illustration. Upload story photo >

Live Poll

Does a decline in quarterly revenue decrease your trust in a company's long-term financial stability?

Fortrea Holdings Inc. reported $691.5 million in revenue for the third quarter of 2026, marking a 1.4% decline compared to the same period in the prior year. The company also announced its financial outlook for the remainder of the year.

Why it matters

The contraction in quarterly revenue highlights the ongoing financial performance challenges for this contract research organization as it navigates current market conditions. Operators should monitor these revenue shifts as indicators of broader demand trends in clinical trial services.

Fortrea Holdings Inc. reported $691.5 million in revenue for Q3 2026, representing a 1.4% decline compared to the prior year. Non-GAAP earnings per share reached 28 cents for the quarter.

The players

Fortrea Holdings Inc.

A global contract research organization providing clinical trial management and consulting services to the pharmaceutical and biotechnology industries.

The details

The firm recorded adjusted non-GAAP earnings per share of 28 cents during the third quarter. Looking ahead to the full 2026 fiscal year, Fortrea anticipates revenue between $2.665 billion and $2.690 billion. Management also provided an adjusted EBITDA forecast in the range of $210 million to $218 million for the full year.

Q3 2026: The reporting period for the quarterly financial results.
2026: The full-year period covered by the company's financial outlook.

Market Landscape

Fortrea Holdings Inc. results reflect a 1.4% revenue decline, marking a departure from the historical growth patterns often observed in the clinical research industry. This performance provides a new data point for evaluating competitive pressure within the outsourced drug development sector.

Operators in the pharmaceutical service sector should factor in the revised full-year revenue outlook of up to $2.690 billion when planning capacity or vendor requirements. Monitoring these shifts in EBITDA and earnings is essential for assessing the stability of long-term contract partners.

The takeaway

Fortrea Holdings Inc. demonstrates the current volatility facing contract research firms with its reported year-over-year revenue dip. Managers should track annual revenue guidance against the $2.665 billion to $2.690 billion forecast to gauge the ongoing health of the clinical trial market.